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1. Introduction 
As with monogenic diseases, hemophilia A and hemophilia B have a direct relationship 
between factor VIII and factor IX gene mutations, respectively, and their causative effect 
on protein deficiency either in function or reduced antigen level in plasma. These aspects 
are related to, but do not totally explain, a more complex clinical phenotype such as the 
age of initial symptom onset, bleeding tendency, inhibitor development, arthropathy 
tendency, carrier bleeding symptoms, etc., which currently are critical complications 
under study in various clinical protocols in order to improve medical care in patients with 
hemophilia. 
The complex relationship between clinical behavior and genetics of hemophilia  
is changing the approach to diagnosis and research methods, expanding the scope  
of analysis to other related genes (bleeding tendency, immune system, regulatory genes  
of X-chromosome expression, etc.). In addition, novel functional approaches can provide 
prognostic parameters of clinical behavior such as gene expression assays  
and biochemical analyses including kinetics of inhibitors to factor VIII or thrombin 
generation assay by the standardized method of calibrated automated thrombography. 
This method describes the overall clotting capacity of patients’ plasma in vitro and  
ex vivo. This chapter will focus on certain studies regarding genotype-phenotype 
interactions in hemophilia that have been applied in Mexican hemophilia families for 
molecular diagnosis and genetic counseling. These studies have also been used  
to determine prognostic factors for clinical behavior and treatment response in 
hemophilia patients in order to improve hematological management as well as to 
optimize the use of therapeutic resources, an important consideration in developing 
countries such as Mexico.  
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2. Mutation–phenotype correlation in hemophilia 
2.1 Origin of mutations in hemophilia 
Because of the high mutation rate of factor VIII gene (2.5–4.2 x 105), ~50% of the severely 
affected families have only one affected case (isolated), pointing to a recent mutation 
occurring in the grandparental or parental generation. Family studies reveal that most 
mutations in hemophilia A originate in male germ cells with a predominance of point 
mutations. Some deletions occur in female gametes and de novo mutations may occur in 
early embryogenesis from a somatic or germinal mosaicism. This mechanism, if minor, 
remains underestimated by routine analysis and originates predominantly from females in 
the case of somatic mosaicism. This may represent a frequent event in hemophilia that must 
be considered in genetic counseling of isolated cases that mainly involve point mutations 
(Leuer et al., 2001). 
In the case of factor IX gene, a considerably lower mutation rate than for factor VIII has been 
reported (3.2 x 109) (Koeberl et al., 1990). However, in hemophilia B there is also a high 
proportion of recent germline mutations originating in the last three generations of isolated 
cases that have been studied in different populations. A similar mutation pattern has been 
found, suggesting an endogenous mechanism for the genetic changes in factor IX gene 
causing hemophilia B. The endogenous mechanism indicates that genetic characteristics of 
the gene (rather than environmental conditions) account for most human germline 
mutations (Sommer 1995, as cited in Jaloma-Cruz et al., 2000). Point mutations are the most 
common mutations in hemophilia, being present in >90% of the patients. This is followed by 
deletions in 5-10% of the cases. Less frequent are the insertion/inversion rearrangements 
with the exception of intron 22 inversion of factor VIII gene in hemophilia A. This is the most 
common genetic rearrangement demonstrated in severe disease, comprising 40-50% of cases 
(Bowen, 2002).  
2.2 Mutation pattern in hemophilia 
There is a high degree of heterogeneity in the location and type of mutations in factor VIII 
and factor IX genes causing hemophilia; >90% are located in coding and promoter regions as 
well in junction sites of intron-exon. Types of mutation and their relative frequencies are 
determined by genetic mechanisms according to the genetic sequence (mutation hot-spots 
such as CpG dinucleotides, gene size, nucleotide repeats, etc.). A general pattern of 
mutations is found as follows: single nucleotide changes: transitions > transversions; 
deletions > insertions > complex rearrangements (Sommer, 1995, as cited in Jaloma-Cruz et 
al., 2000). 
2.3 Unusual mutagenesis mechanism in the Mexican hemophilia B population 
From a study of nine independent Mexican hemophilia B families (Jaloma-Cruz et al., 2000), 
we found a particular mechanism of recurrent mutagenesis by four single independent 
substitutions in two similar non-CpG sites at nucleotide positions 17,678 (C88Y, C88F) and 
17,747 (C111S, C111Y) of factor IX gene (Table 1). Using a statistical test considering a 
mutation target of 439 nucleotide position non-CpG sites in the coding region of factor IX 
(where >96% of factor IX gene mutations occur), it was demonstrated that the observed 
mutations were nonrandom events (p = 0.0004) (Jaloma-Cruz et al., 2000). These mutations 
were considered as first-line evidence of a mechanism of recurrent mutation in hemophilia 
involving unusual hot-spot sites. It will be interesting to continue these types of studies in 
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epidemiological analyses to explore the subjacent mechanism of causative mutagenesis in 
particular populations.  
 
 
Table 1. Summary of Mutations in Mexican Patients with Hemophilia B  
aS = Severe; M = Moderate; N = No data (White, 2001). 
bHB760: the sequence change at 17678 was present in the index patient and mother, but absent from 
both maternal grandmother and grandfather. The 3'RY(i) polymorphism, established the maternal 
grandfather (MF) as the origin. HB762: the mother was a carrier, but the sequence change at 20,519 was 
not present in 13 maternal aunts and uncles or in the maternal grandfather. Extragenic polymorphisms, 
DXS 1211 and DXS 1232, established the maternal grandmother (MM) as the origin. 
HB765: the sequence change at 17,747 was present only in the index patient, establishing the mother (M) 
as the origin. 
cMseI/BamHI/HinfI/XmnI/TaqI/3'RY(i)/HhaI. 
dLD, large deletions. The MCF2 gene, located about 80 kb downstream of the F9 transcription start site 
is present in HB759 but absent in HB766, indicating deletions of about 60 kb and more than 100 kb, 
respectively. 
eMicrodeletion resulting in frameshift (fs) at G388 and stop codon at I408. 
(Modified from Jaloma et al., 2000) 
2.4 Genotype-phenotype correlation in hemophilia 
As with monogenic diseases, hemophilia A and B have a direct relationship between factor 
VIII and factor IX gene mutations, respectively, and their causative phenotype effect at the 
clinical level secondary to the caused protein deficiency, either in function or reduced 
antigen level in plasma (Koeberl et al., 1990). 
In general, there is good correlation between the type of mutation (location in the amino-
acid position and domain in the protein) and their functional outcome, yielding a 
predictable clinical severity. However, some authors affirm that this correlation is rare and, 
in the majority of cases, a clear correlation has not been shown (Bowen, 2002) with the 
exception in a very few cases of self-evident molecular defects such as large deletions, 
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nonsense mutations causing premature translation stop and truncated protein, corrupted 
mRNA splicing, etc. 
Because of the difficulty in presenting a clear correlation, in 2001 the International 
Committee of Standardization in Thrombosis and Hemostasis established the clinical 
severity classification according to the clotting level in plasma and not to clinical 
manifestations (more complex phenotype). A direct relationship between the genetic defect 
and protein activity is expected (Table 2) (White, 2001). 
 
 
Table 2. Classification of hemophilia A and B. Normal is 1 IU/ml of factor VIII:C (valid also 
for factor IX:C) as defined by the current World Health Organization International Standard 
for Plasma Factor VIII:C (as distributed by The National Institute for Biological Standards 
and Control, Potters Bar, Hertsfordshire, UK). (Modified from White et al., 2001). 
The limitation of the criterion of clotting activity of deficient factors VIII and IX to establish 
clinical severity in hemophilia may be due to the fault of reproducibility of laboratory tests 
of coagulation. These may be due to assay problems such as sample management 
(preanalytical factors), quality of reagents, zero point activity, etc., that must be carefully 
controlled in order to have a confident result and the relationship with clinical severity 
(Barrowcliffe, 2004). These problems also lead to investigation of newer methods with closer 
physiological correlation, higher sensitivity and less coefficient variation values such as 
thrombin generation test or thromboelastography (Barrowcliffe, 2004).  
3. Structure-function relationship of factor IX gene mutations at the 
subcellular level 
During the search for mechanisms that cause mutations in hemophilia and its impact on the 
relationship between the structure-function of mutant proteins, several analytical 
investigations have been developed at the cellular level of the interaction of factor VIII 
(FVIII) and factor IX (FIX) mutant proteins with other intracellular components involved in 
their posttranslational processing and secretion. 
3.1 Structure-function relationship in mutant FIX proteins  
In the study of factor IX mutations causing a severe phenotype, two mutations were 
analysed. These were located at the first and second epidermal growth factor (EGF) domain, 
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C71Y and C109Y, respectively, both affecting a cysteine site and, therefore, the folding 
native structure of FIX protein (Enjolras et al., 2004). Different analyses of posttranslational 
processing and intracellular trafficking revealed that neither mutant was secreted nor 
accumulated in the intracellular space due to their interaction with chaperones from 
endoplasmic reticulum (ER) that cause their arrest and lead to their degradation into 
proteasomes (Enjolras et al., 2004). A related study was carried out for the relevant factor IX 
mutations identified in Mexican hemophilia B patients that were caused by a recurrent 
mutagenesis at non-CpG sites (Jaloma-Cruz et al., 2000). They also affected the structure-
function of FIX by changes of a cysteine position in the second epidermal growth factor 
(EGF2) domain of factor IX gene (C111S and C111Y mutations). 
3.2 Directed mutagenesis and functional analysis of FIX mutations 
The two mutations at cysteine 111 cause severe hemophilia B in Mexican hemophilia B 
patients. To analyze their impact on the structure-function relationship of FIX, the effect of 
inhibitors of intracellular trafficking was studied comparing C111 wild-type (wt) and the 
C111S and C111Y mutations that were inserted by directed-site mutagenesis into an 
expression vector (pcDNA 3.1®) containing factor IX wild type (wt) gene. Transfection by 
Fugene6® was evaluated in Cos-7 cells after 48 h. Intracellular production and secretion of 
FIX were quantified by ELISA assay. Transfected cells were incubated for 6 h with different 
inhibitors of intracellular trafficking classified by their solubility properties; hydrosolubles: 
NH4Cl and leupeptin, which are lysosomal inhibitors, and liposolubles: Brefeldin A, that 
blocks protein transport from ER to the Golgi complex; cycloheximide, inhibitor of synthesis  
protein, N-acetyl-leu-leu-norleucinal (ALLN) and clasto-lactacystin beta-lactone (calpain), 
both proteasomal inhibitors (Mantilla-Capacho et al., 2008). 
The mutants showed a decreased FIX secretion (20%) and intracellular accumulation of 
140% (C111Y) and 160% (C111S) with respect to wt factor IX. The inhibitors caused higher 
intracellular accumulation, which evidenced a degradation primarily in lysosomes (NH4Cl) 
of both mutants. C111S mutation showed a strong effect of Brefeldin A, suggesting an 
adequate transport from ER to Golgi complex in contrast to C111Y, which showed higher 
proteasomal degradation, evidenced by the effect of ALLN (Figure 1) (Mantilla-Capacho et 
al., 2008).  
The study concluded that the disruption of the disulfide bond in the mutants has an 
important effect on the native folding of FIX due to their accumulation in the intracellular 
space in regard to wt FIX. C111Y showed a higher impact than C111S on its transport 
through ER with a predominant degradation at proteasomes (Mantilla-Capacho et al., 2008). 
Other factor IX mutations previously identified in the Mexican population have also been 
analyzed using related approaches for the analysis of genotype-phenotype interaction at the 
subcellular level. These demonstrate evidence of posttranscriptional regulation mechanisms 
and behavior of mutant proteins that reveal the importance of key sites of protein function. 
Further studies are essential for a better understanding of the properties of FVIII and FIX 
and the biochemical phenotype of hemophilia. 
4. Molecular diagnosis for carrier testing 
The wide mutational heterogeneity in both types of hemophilia compels the use of 
intragenic polymorphisms for carrier testing. Different polymorphisms have been described 
in factor VIII and factor IX genes such as single nucleotide polymorphisms (SNPs) identified  
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Fig. 1. Effect of inhibitors of cellular trafficking on factor IX production (intracellular and 
secretion) of C111S and C111Y mutations of factor IX gene. Significant effect is highlighted 
by red stars. 
by restriction fragment length enzyme polymorphisms (RFLPs), variable number of tandem 
repeats (VNTRs) or microsatellites defined by the length of the repeated units [1-4 nucleotides, 
short tandem repeats (STRs), >5 nucleotides, VNTRs] (Bowen, 2002). According to recent 
knowledge of the human genome and the high variability among individuals, a difference is 
expected of one base for every 1250 base pairs on average. According to the gene sizes of factor 
VIII (186 kb) and factor IX (34 kb), both genes would be expected to be ~144 and 27 SNPs, 
respectively. However, fewer polymorphisms have been identified, which means a paucity of 
polymorphisms or a detection problem, this last reason being more plausible because new 
polymorphisms continue to be described (Figure 2) (Bowen, 2002; Kim, 2005). 
4.1 Linkage analysis in hemophilia A and B 
Automatic sequencing methods and high-yield analysis techniques of the human genome 
have extended the detection of mutations in both types of hemophilias. In the case of factor 
VIII and factor IX genes, diverse polymorphisms have been used for carrier diagnosis as a 
low cost, alternative and rapid method. Use of intragenic polymorphisms by linkage 
analysis shows high confidence (>95%) according to the linkage disequilibrium between   
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Fig. 2. Polymorphisms of factor VIII and factor IX genes. Some of the known polymorphisms 
in the human genes for (A) factor VIII and (B) factor IX.  
a) Factor VIII gene: intron 7 G/A, intron 13 (CA)n, intron 18 BclI, intron 19 HindIII, intron 22 XbaI A, 
intron 22 MspI A, intron 22 (CA)n, intron 25 BglI, 3’MspI.  
b) Factor IX gene: 5’ -793 G/A, 5’ BamHI, 5’ MseI, intron 1 DdeI, intron 3 XmnI, intron 3 BamHI, intron 4 
TaqI, intron 4 MspI, exon 6 MnlI, exon 8 (RY)n, and 3’ HhaI. 
(Figure and source references of polymorphisms as cited in Bowen, 2002). 
polymorphisms and the causative mutation of the hemophilia (Mantilla-Capacho et al., 
2005). This strategy requires sampling of all family members to trace the segregation of the 
polymorphism linked to the mutated X-chromosome for factor VIII or factor IX genes. The main 
limitation of the strategy is the informativeness of the polymorphism that is defined by its 
heterozygosity in a population, with a maximum value of 50%, corresponding to the highest 
probability of finding two alleles in the obligated carrier of one family. The described 
polymorphisms must be analyzed in each population in order to identify the useful markers.  
4.2 Carrier diagnosis strategy in the Mexican population 
For molecular analysis of carrier diagnosis, we developed a strategy based on intragenic 
polymorphism linkage analysis. According to their diagnostic informativeness percentage in 
the Mexican population, for factor VIII gene we initially used the following: the 
microsatellite of (CA)n of intron 13 (75%) and the RFLPs BclI- intron 18 (50%) and AlwNI- 
intron 7 (20%) (Mantilla-Capacho et al., 2005). 
In order to improve the technical feasibility and informative level of carrier diagnosis in 
Mexican families with hemophilia A, we used the method of Kim et al. (2005) based on 
fluorescent PCR of four intragenic dinucleotide-repeat polymorphisms analyzed by 
automated Genescan®. Preliminary data show that the use of dinucleotide repeats at introns 
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1, 13 and 22 achieved a significant increase in informativeness (>85%), which is useful for 
carrier testing in more than 200 hemophilia A families (González-Ramos et al., 2010).  
 
 
Fig. 3. Intragenic polymorphisms of factor VIII gene used for carrier diagnosis in hemophilia 
A in the Mexican population 
In the case of hemophilia B we used four RFLPs of factor IX gene in order of heterozygosity: 
HhaI-3 terminal region (50%); NruI and SalI in the promoter region (40-20%); TaqI-intron D 
(30%) and HinfI-intron A (25%). Together the polymorphisms are highly informative and 
most families (>90%) are diagnosed for carrier status using these markers (Mantilla-Capacho 
et al., 2005). 
4.3 Detection of common mutations in hemophilia A 
The inversion of intron 22 in factor VIII gene is the most common mutation in hemophilia A. 
It is the cause of the severe form of the disease due to the inversion of factor VIII gene at 
intron 22 and its disruption from the rest of the gene caused by an intrachromosomal 
recombination of a region at intron 22 and two copies located at 400 kb toward the telomeric 
region (Lakich et al., 1993; Naylor et al., 1993). This rearrangement is responsible for 40-50% 
of severe hemophilia A cases. A similar mechanism at intron 1 accounts for 1-5% of severe 
cases (Bagnall et al., 2002). 
Using the method of long-distance PCR (Liu et al., 1998) we found a frequency of 45% of the 
intron 22 inversion in patients with severe hemophilia A. We did not find the intron 1 
inversion in the Mexican population with severe hemophilia A (n=65) (Mantilla-Capacho et 
al., 2007). Intron 22 inversion as the complex rearrangement causing the absence of FVIII 
protein has been identified as a moderate genetic risk factor for inhibitor development in 
patients with the severe form of the disease (Mantilla-Capacho et al., 2007). 
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Fig. 4. Intragenic polymorphisms of factor IX gene used for carrier diagnosis in hemophilia B 
in the Mexican population 
A new procedure was recently developed for the simultaneous detection of both inversions 
and the discrimination between distal and proximal rearrangements of intron 22 inversions 
(inv22-type 1 and inv22-type 2, respectively) by a novel inverse shifting PCR (IS-PCR) 
approach (Rossetti et al., 2008). This genotyping method includes the following: a) genomic 
digestion by BclI enzyme followed by b) self-ligation of the digested fragments containing 
the sequences of intron 22 of factor VIIII gene and their telomeric copies and c) a final  
PCR standard with different primers to detect normal and recombined fragments. The 
method also includes complementary diagnostic testing for detection of nondeleterious 
variants (normal products and duplications) produced by intron 22 rearrangements 
(Rossetti et al., 2008).  
This procedure has recently been established in our laboratory and tested in a group of 24 
patients with severe hemophilia A from independent families showing similar results in 
frequencies previously reported for the inversions in the Mexican population of severe 
hemophilia A patients (46% intron 22 inversion; 0% intron 1 inversion). From this study it 
was also possible to discriminate between both types of inv22. We found a frequency of 73% 
of type 1 inv22 and 27% of type 2 inv22 (Valdés-Galván, 2011). A high-quality DNA sample 
and the self-ligation step conditions are important in order to obtain consistent results. IS-
PCR is the first-choice method for genetic analyses and carrier diagnosis in familial and 
sporadic cases of severe hemophilia A. 
5. Hemorrhage phenotype attenuation in hemophilia by prothrombotic genes 
In monogenic diseases such as hemophilia A and B, good correlation is expected between 
genotype and phenotype, i.e., type of mutation in factor VIII and factor IX genes causing 
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functional deficiency of the respective proteins to determine clinical severity. This is valid at 
the biochemical level (clotting activity) but not directly related to the bleeding symptoms in 
patients because there is clinical variability due to components other than deficient FVIII 
and FIX (White, 2001).  
Different reports and meta-analyses have shown that, despite similar mutations in factor VIII 
or factor IX genes, there is an expected clinical variability in hemophilia. This is due to 
natural anticoagulant and fibrinolytic genes (Shetty et al., 2007, as cited in López-Jiménez et 
al., 2009) or the concomitant presence of mutations causative of prothrombotic risk factors 
(Factor V G1691A and Factor II 20210A). These cause the attenuation of hemorrhagic 
symptoms such as onset of bleeding episodes and frequency of hemarthroses as well as 
treatment requirements (Nichols et al., 1996; Kurnick et al., 2007; Tizzano et al., 2002; as cited 
in López-Jiménez et al., 2009) and from an extensive review of literature, FVLeiden has 
demonstrated to decrease hemophilia severity most consistently (Van Dijk et al., 2004). 
These studies have also demonstrated thrombosis risk in hemophilia patient carriers of 
prothrombotic genes such as reported for a patient with hemophilia B who suffered a 
venous thromboembolism as a result of exposure to high doses of replacement treatment 
during a surgical procedure (Pruthi et al., 2000).  
Descriptive studies of hemophilia A and B families with some affected members with a 
striking attenuation of bleeding symptoms have demonstrated evidence of attenuation of 
bleeding phenotype attributable to the presence of prothombotic markers such as Factor V 
G1691A and Factor II 20210A. To some extent, these are also related to allelic polymorphisms 
of the methylenetetrahydrofolate-reductase (MTHFR) gene related to the activity of the 
enzyme (C677T) and the regulatory domain (A1298C). From a study in Mexican families with 
hemophilia A and B, the effect of Factor V G1691A and Factor II 20210A was demonstrated in 
the attenuation of hemorrhagic symptoms in hemophilia patients (López-Jiménez et al., 2009). 
The attenuation of hemophilia phenotype was mainly observed in the delay of bleeding 
symptom onset and secondly in a lower frequency of bleeding episodes (López-Jiménez et al., 
2009).  There was no evidence of an additional effect of attenuation on hemorrhagic symptoms 
by MTHFR polymorphisms, confirming the main contribution of Factor V G1691A and Factor 
II 20210A mutations, which are modulating genes of the hemophilia phenotype. On the basis 
of the feasible molecular analysis by routine PCR of prothrombotic genes and their relative 
frequency in different populations (1-5%), screening is recommended in those hemophilia 
patients with noncongruent clinical behavior in regard to severity by clotting activity of factor 
VIII or factor IX proteins. 
6. Thrombin generation assay to evaluate clinical severity and treatment 
response in hemophilia 
In search of objective criteria for the classification of clinical severity in hemophilia and 
prognostic factors with regard to treatment response in patients, functional approaches 
reflecting overall hemostatic behavior have shown important usefulness in providing 
parameters for clinical evaluation and investigation. The fundamental premise of the 
method is based on thrombin as a central molecule of coagulation whose increase or 
decrease reflects any alteration from the hemostasis equilibrium caused by hemorrhagic or 
thrombotic factors. The thrombin generation assay (TGA) was originally analyzed as a 
research source beginning in the 1950s with significant limitations due to labor-intensive 
requirements by subsampling and its application being restricted to only very specialized 
laboratories (Hemker, 2000). 
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Subsequently, Hemker and coworkers (2003) continued the research and improvement of 
the method until automation in calibrated automated thrombography.  
6.1 TGA and correlation with clinical severity in hemophilia 
Using calibrated automated thrombography, we studied 23 hemophilia A patients from nine 
families. Correlation analysis was done for clinical severity (according to an annual number 
of hemarthroses) and by the clotting activity of FVIII. The study showed that TGA was not 
able to discriminate differences among familial members but showed correlation with the 
general bleeding tendency of the clinical severity of patients according to FVIII:C levels 
(Beltrán-Miranda et al.,  2005).  Different parameters of the TGA may be useful to correlate 
with clinical severity in addition to endogenous thrombin potential (ETP), such as the peak 
and rate of thrombin generation.  
6.2 TGA and inhibitor behavior in hemophilia A patients 
In search of prognostic factors of treatment response in patients positive to inhibitors, we 
describe the kinetic study of FVIII:C inhibitors and TGA in vitro in poor platelet plasma 
(PPP) of hemophilia A patients positive to inhibitors to correlate with clinical parameters of 
response to available treatments in Mexico (Luna-Záizar, 2008). 
The activity of FVIII:C in plasma was measured by one-stage clotting method and inhibitors 
to factor VIII was investigated using the Nijmegen-Bethesda method. Inhibitor kinetics was 
determined by plasma dilutions. TGA was measured in the inhibitor-positive PPP 
previously spiked and incubated with two treatments: FVIII and Activated Prothrombin 
Complex Concentrate (APCC, FEIBA™) by the Calibrated Automated Thrombography. 
Response to treatment by clinical criterion was assessed by 30 hematologists from 25 health 
institutions according to a questionnaire that assessed specific parameters of reduction of 
bleeding and improvement from the damage by decreasing pain and inflammation. We 
detected inhibitor antibodies in 71 patients (37.8%): 46 high responders (5-1,700 NB-U/mL) 
and 25 low-responders (0.6-4.7 NB-U/mL). When the plasmas of patients with high-
responding inhibitors were incubated with the therapeutic product we found some changes 
in the thrombogram parameters. We found a significant association between inhibitor type 
and clinical treatment response to FVIII (p=0.0003, n=42) and between type kinetics vs. FVIII 
response evaluated with ETP (p=0.0021, n=47). 
Concordance of FVIII response under clinical criteria and ETP was 71%, 86% and 67% 
among patients with type I, II and III inhibitors, respectively. The inhibitor kinetics was a 
prognostic parameter of response to FVIII replacement therapy in 74% of the patients.  
The change in the ETP parameter showed a relationship between inhibitor type and  
clinical treatment response. TGA permitted an individual evaluation of treatment  
response and showed usefulness such as objective criterion of responsiveness for a better 
selection of therapeutic resources, such as observed in one studied patient (Figure 5) (Luna-
Záizar, 2008). 
Other studies have also demonstrated the usefulness of TGA for monitoring treatment 
response to bypassing agents in patients positive to inhibitors in approaches carried out in 
vivo (Varadi et al, 2003 as cited in Dargaud et al., 2005) and ex vivo (Dargaud et al., 2005, 
2010), which use the TGA as an important tool for direct clinical application in regard to 
medical decisions such as treatment doses and management of hemophilia patients with 
inhibitors.  
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Fig. 5. TGA parameters in a hemophilia A patient positive to inhibitors and treatment 
response. Response to factor VIII and APCC by ETP increment from basal levels evaluated 
in platelet poor plasma of hemophilia A patients with inhibitors (Luna-Záizar, 2008). 
7. X-chromosome inactivation pattern in hemophilia carriers with  
bleeding symptoms 
Because hemophilia A and B are X-linked recessive disorders, males are affected, whereas 
females are carriers and usually asymptomatic due to the lyonization phenomenon. The 
lyonization process allows expression of only one allele of the genes located in the X active 
chromosome. For this reason, females are mosaic for the expression of maternal and 
paternal alleles and each chromosome contributes ~50% of gene expression (Puck & Willard, 
1998), which is sufficient to prevent females from the manifestations of the disease. X-
chromosome inactivation is a stochastic event that occurs early in female embryonic 
development to achieve dosage compensation with males. Certain genetic mechanisms 
affect the normal process causing a skewed X-inactivation pattern that has clinical relevance 
in female carriers of X-linked recessive disorders such as hemophilia (Mundo-Ayala & 
Jaloma-Cruz, 2008).  
In probabilistic terms, the X-inactivation process follows a normal distribution pattern; 
however, it is possible to observe skewed and extremely skewed values (Amos-Landgraf et 
al., 2006). In some instances, skewness is due to the variation of the process itself when the 
inactivation ratio among X chromosomes is close to the mean value (75:25) or (80:20). 
Skewness higher than these proportions may indicate a genetic cause (Amos-Landgraf et al., 
2006). 
Genetic mechanisms that can explain extreme skewness of the X-inactivation process 
include mutations in genes that participate in the lyonization phenomenon. A mutation on 
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the promoter region of the XIST gene has been described that affects the randomness of the 
process resulting in a skewed X inactivation (Plenge et al., 1997; Tompkins et al., 2002).  
 
 
Fig. 6. Scheme of the HUMARA assay. Analysis of the X-inactivation pattern using DNA 
samples and the Gene-Scan software (Applied Biosystems).  
7.1 Molecular diagnosis of skew in the X-chromosome inactivation pattern in 
symptomatic hemophilia carriers           
A symptomatic hemophilia carrier may request genetic counseling due to the presence of 
bleeding such as menorrhagia, epistaxis, bruising, gingivitis, etc. (Mundo-Ayala & Jaloma-
Cruz, 2008). In case of symptoms in a hemophilia B carrier and after ruling out von 
Willebrand disease (in a symptomatic carrier of hemophilia A) or chromosomal anomalies 
such as Turner syndrome to explain the bleeding symptoms, geneticists and molecular 
biologists should consider analysis of the X-inactivation pattern in the DNA samples of the 
patient and her parents (Mundo-Ayala & Jaloma-Cruz, 2008).  
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The gold standard for the analysis of the X-inactivation pattern is the human androgen 
receptor assay (HUMARA) developed by Allen et al. (1992). We recently used a modified 
protocol for automatic genotyping of HUMARA by fluorescent Genescan® described by 
Karasawa et al. (2001) with some modifications to achieve a precise reading in the GC-rich 
region of the polymorphic region of HUMARA (Ishiyama et al., 2003) and to improve the 
yield of PCR product and digestion to discriminate the active/inactive alleles by 
methylation (Mundo-Ayala & Jaloma-Cruz, 2008; Mundo-Ayala, 2010). The methodology is 
illustrated in Figure 6 and our group has described it in detail for the automatic fluorescent 
Genescan® (Mundo-Ayala & Jaloma-Cruz, 2008; Mundo-Ayala, 2010). Use of this technique 
in bleeding carriers and females with hemophilia allows identifying whether their 
hemorrhagic symptoms are due to an unfavorable lyonization.  
7.2 Analysis of a Mexican hemophilia A family with a symptomatic carrier  
We describe the study of X-chromosome inactivation pattern in a family with hemophilia A 
and a symptomatic carrier (Figure 7). Members of this family are affected males, and two of 
four sisters (II:6 and II:7) were confirmed as carriers after molecular diagnosis by factor VIII 
polymorphisms. Sister (II:7) is a symptomatic carrier who presented clinical manifestations 
of hemophilia A and a significantly reduced level of FVIII:C (2.5%). Using molecular 
analysis to determine the X-inactivation pattern, a nonrandom X inactivation was found. 
The results showed that the healthy X chromosome inherited from the father was 
preferentially inactive, whereas the affected chromosome from maternal origin was 
expressed in ~96% of the patient’s total organism (Mundo-Ayala, 2010). 
 
 
Fig. 7. Symptomatic carrier from a family of moderate hemophilia A studied by HUMARA 
assay. The obligate carrier (I:1) had HUMARA alleles of 276/285 bp. There were three 
affected males; the propositus (II:4) is indicated with an arrow. There were four females; two 
(II:6, II:7) were carriers of hemophilia A as confirmed by molecular diagnosis. Symptomatic 
carrier (II:7) showing an extreme X-inactivation pattern that explains her bleeding 
manifestations due to the preferential inactivation of the paternal X chromosome. 
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Clinical bleeding manifestations in the symptomatic carrier (II:7) of this family with 
hemophilia A occur as a result of the nonrandom X inactivation pattern, which favorably 
silences the healthy X chromosome inherited from her father. After a negative result of 
mutations at the promoter region of XIST gene, the molecular origin remains unknown of 
the skewness in the symptomatic carrier (Mundo-Ayala, 2010). 
From the study of different symptomatic carriers of hemophilia from Mexican families, we 
conclude that it is important to provide genetic counseling due to the possibility of 
inheriting a nonrandom pattern of X-chromosome inactivation. 
Clinical implications from the skewed pattern of X-chromosome must be considered for 
genetic counseling and hematological control in symptomatic carriers. Furthermore, analysis 
of X-inactivation pattern is necessary for understanding the human X-chromosome 
inactivation process (Mundo-Ayala & Jaloma-Cruz, 2008). 
8. Conclusions 
The various studies presented in this chapter emphasize the importance of a comprehensive 
overview in hemophilia, considering multiple interactions among genes, metabolic 
pathways and different approaches including molecular data, biochemical analysis and 
clinical aspects. All these factors are important in order to consider an integrative evaluation 
of the clinical aspects of hemophilia so as to improve medical management and to obtain 
prognostic factors for clinical behavior and treatment response. 
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